Discovery of BMS-641988, a Novel Androgen Receptor
Antagonist for the Treatment of Prostate Cancer

Aaron Balog (1371318); Andrew Nation (1665331); Cheryl Rizzo (1665340); Christian L. Holst (1665301); David Fairfax (1665337); George Trainor (1601473); Georgia Cornelius (1429912); Gregory
S. Martin (1665319); Gregory D. Vite (1436365); Jack Gougoutas (1665313); Janet Dell-John (1665307); John D. DiMarco (1665322); Lana M. Rossiter (1665328); Liang Schweizer (55120); Marco Gottardis (1665304); Mark E. Salvati (1665334); Ricardo Attar (1665310); Richard Rampulla (1601455); Stanley R. Krystek (1665316); Steven Spergel (1665325); Thomas Spires (1665298); Weifang Shan (1371309)

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

Abstract

BMS-641988 (<b>23</b>) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist <i>in vitro</i>. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/22021...

Last time updated on 12/02/2018